Bavarian Nordic A/S focuses on the development, manufacturing and commercialization of cancer immunotherapies and vaccines for infectious diseases. It specializes in cancer immunotherapy which includes cancer pipeline, which focuses on therapeutic vaccines for breast, lung, ovarian and prostate cancer. Its products include IMVAMUNE for Ebola, HPV, HBV, and HIV diseases. The company was founded in 1994 and is headquartered in Kvistgaard, Denmark.

Octapharma is a privately-owned global human proteins manufacturer headquartered in Lachen, Switzerland. Since its establishment in 1983 the company has been dedicated to improving the lives of patients. Octapharma was founded in 1983 on the fundamental principle of improving the lives of patients. Since then we have remained focused on our collective responsibility for the trust instilled in us by physicians and patients worldwide. In 2012, the Octapharma Board identified the core strategic pillars which will lead to the achievement of the organization’s ambitious long term goals.

CEVEC is a center of expertise for the production of biopharmaceuticals using a unique human cell-based expression system. CAP-Go enables the production of proteins “beyond antibodies”. Complex, glycosylated proteins represent a significant portion of the human proteome and are notoriously difficult to express in conventional cell lines such as CHO. The CAP-Go expression platform comprises a portfolio of glyco-optimized human suspension cell lines for the highly efficient production of a broad range of difficult to express recombinant proteins with authentic human post-translational modifications or on demand tailor-made glycosylation patterns.

Roche Diagnostics GmbH, part of Roche Holding AG, is a company headquartered in Mannheim, Germany, involved in laboratory analytical instruments. Andreas Schmitz and Claus Haberda are the current co-CEOs of the firm. On January 01, 1999 Roche Holding AG acquired Roche Diagnostics GmbH.

Janssen Vaccines & Prevention BV manufactures and supplies biopharmaceutical products. The company was founded in 2000 and is headquartered in Leiden, the Netherlands.

Nestec SA, a subsidiary of Nestlé SA, is a Swiss company located in Vevey. The firm manufactures nutrition food products.

The University of California is the nation's best public university system, delivering top-notch research and innovation to California (and the world).

HumanZyme, Inc. manufactures biological products. It develops a line of authentic human recombinant proteins for various life science applications. Its products include catalog, cytokines, cytokines media kit, HSA, antibodies, and custom proteins. The firm also offers applications including stem cell research, immunology research, and human cellular therapy. The company was founded by Jian Wen Liao in 2005 and is headquartered in Chicago, IL.

Ferring BV offers pharmaceutical products. It offers medicines in Gynaecology, Gastroenterology, Endocrinology and Urology. The company was founded in 1984 and is headquartered in Hoofddorp, Netherlands.

Octapharma Biopharmaceuticals GmbH, part of Octapharma AG, is a company headquartered in Heidelberg, Germany. The firm develops biopharmaceuticals. It was founded in 1997. Christoph Kannich and Carsten Ratzel are the current co-CEOs of the firm.\nThe company says this about itself: Expertise, experience and commitment are the basis for excellent work and perfect results. Since the founding of Octapharma Biopharmaceuticals GmbH in 1997, our experience in the area of research and development in the field of human cell lines has evolved extensively, resulting in the maturation of an effective, product-oriented biotechnology firm. Our core competence is the development of recombinant pharmaceuticals as a modern alternative to plasma products. The demand for recombinant therapies is steadily increasing. The proof from market statistics is quite impressive: from 2002 to 2005, the market share for recombinant proteins in 25 research companies rose by approximately 8% overall. The example of the Factor VIII product, which is derived from plasma, demonstrates this exceptionally clear-the shift of plasma-derived Factor VIII to recombinant Factor VIII was reflected in a turnover share increase and rapid growth of 96%. Our work confirms these trend-setting and innovative discoveries, which undoubtly makes clear that Octapharma Biopharmaceuticals GmbH is on the right path.

Flinders Medical Centre (FMC) is a major public tertiary hospital and teaching school, co-located with Flinders University and the 130 bed Flinders Private Hospital located at Bedford Park, South Australia. It opened in 1976. It serves as the trauma centre for the southern suburbs, and parts of the Adelaide Hills. An around-the-clock emergency retrieval service brings patients to FMC by road or helicopter.

CellFactors Plc is a private company headquartered in Babraham, UK, that develops therapeutic products derived from human cells.

Mochida Pharmaceutical is a drug manufacturing company. Their pharmaceutical business aims to develop and market a broad spectrum of innovative new drugs. They also offer creates skin care products for the general public, and these are supplied through pharmacies, and drugstores.

Bristol-Myers Squibb Company, through its subsidiaries, engages in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of pharmaceuticals and nutritional products. The company operates in two segments, Pharmaceuticals, and Nutritionals. The Nutritionals segment is operated through the company's subsidiary Mead Johnson Nutrition Company (Mead Johnson). The Pharmaceuticals segment is made up of the global pharmaceutical and international consumer medicines business.

Horizon Discovery Group PLC is a UK life science company that uses gene editing and gene modulation platforms to produce cells, applying them in research and clinical applications that advance human health. The Company’s gene editing and gene modulation platform, are able to alter almost any DNA sequence or RNA transcription, has generated a catalogue of over 1,000,000 cell and reagent products that help researchers recapitulate the genetic and protein anomalies found in diseases like cancer. These models have been adopted by c12, 000 organizations to better understand of the predictors and drivers of disease and drug response, and by Horizon in a range of services offered to customers, as well as in the Company’s own research R&D pipeline.

Regeneron Pharmaceuticals is a biopharmaceutical company that discovers, develops, and commercializes pharmaceutical products for the treatment of serious medical conditions. The Company has therapeutic candidates in clinical trials for the potential treatment of cancer, eye diseases, and inflammatory diseases, and has preclinical programs in other diseases and disorders. The company’s product portfolio includes EYLEA, an aflibercept injection; ARCALYST, a rilonacept Injection for subcutaneous use; ZALTRAP for metastatic colorectal cancer; trap fusion proteins; and fully human monoclonal antibodies. On March 26, 2012, it was announced that Sanofi and Regeneron are in development with a new cholesterol drug which will help reduce cholesterol up to 72%. Regeneron Pharmaceuticals was founded in 1988 and is currently headquartered in New York, USA.

Warner-Lambert Co. used to manufacture and market pharmaceuticals, consumer health care products & confectionery. Its pharmaceutical products were ethical pharmaceuticals, biological products and hard-gelatin capsules. Its consumer health products were a wide range of products like oral care mouthwash/dental rinses, toothpaste, effervescent denture cleaning tablets, upper respiratory cold & sinus preparations, antihistamines, allergy products and cough syrups/suppressants. The company was headquartered in Morris Plains, NJ.